Market closedADR
Novo Nordisk/$NVO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
$NVO
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
76,826
Website
Novo Nordisk Metrics
BasicAdvanced
$386B
27.59
$3.13
0.19
$1.03
1.82%
Price and volume
Market cap
$386B
Beta
0.19
52-week high
$148.15
52-week low
$78.17
Average daily volume
8.9M
Dividend rate
$1.03
Financial strength
Current ratio
0.74
Quick ratio
0.523
Long term debt to equity
62.497
Total debt to equity
71.636
Dividend payout ratio (TTM)
43.71%
Interest coverage (TTM)
85.29%
Management effectiveness
Return on assets (TTM)
20.56%
Return on equity (TTM)
80.78%
Valuation
Price to earnings (TTM)
27.589
Price to revenue (TTM)
9.577
Price to book
19.46
Price to tangible book (TTM)
86.21
Price to free cash flow (TTM)
39.926
Dividend yield (TTM)
1.19%
Forward dividend yield
1.82%
Growth
Revenue change (TTM)
25.03%
Earnings per share change (TTM)
21.54%
3-year revenue growth (CAGR)
27.29%
3-year earnings per share growth (CAGR)
29.71%
3-year dividend per share growth (CAGR)
29.91%
What the Analysts think about Novo Nordisk
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.
Novo Nordisk Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Novo Nordisk Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Novo Nordisk News
AllArticlesVideos
NVO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Novo Nordisk A/S Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Business Wire·14 hours ago
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
Accesswire·19 hours ago
Novo Nordisk A/S Is Being Sued For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm
Accesswire·19 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closedADR
Upcoming events
Mar31
Novo Nordisk
Dividend·Ex-dividend
Apr8
Novo Nordisk
Dividend·Payment
$1.099206
Per share
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $386B as of February 10, 2025.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 27.59 as of February 10, 2025.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of February 10, 2025, the dividend rate is $1.02575 and the yield is 1.82%. Novo Nordisk has a payout ratio of 43.71% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment is scheduled for April 08, 2025.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.19. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.